Aclaris Therapeutics, Inc.
Symbol: ACRS (NASDAQ)
Company Description:
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
- Today's Open: $2.06
- Today's High: $2.12
- Today's Low: $2.055
- Today's Volume: 895.57K
- Yesterday Close: $2.04
- Yesterday High: $2.14
- Yesterday Low: $2.02
- Yesterday Volume: 1.50M
- Last Min Volume: 205.47K
- Last Min High: $2.075
- Last Min Low: $2.075
- Last Min VWAP: $2.075
- Name: Aclaris Therapeutics, Inc.
- Website: https://www.aclaristx.com
- Listed Date: 2015-10-07
- Location: WAYNE, PA
- Market Status: Active
- CIK Number: 0001557746
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $221.00M
- Round Lot: 100
- Outstanding Shares: 108.33M
- Asset Type: CS
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-08-07 | 10-Q | View |
| 2025-08-07 | 8-K | View |
| 2025-08-05 | 4 | View |
| 2025-08-05 | 3 | View |
| 2025-07-29 | 8-K | View |
| 2025-07-29 | SCHEDULE 13G | View |
| 2025-07-24 | SCHEDULE 13G/A | View |
| 2025-07-17 | SCHEDULE 13G | View |
| 2025-06-30 | 8-K | View |
| 2025-06-09 | 4 | View |
| 2025-06-09 | 4 | View |
| 2025-06-09 | 4 | View |
| 2025-06-09 | 4 | View |
| 2025-06-09 | 4 | View |
| 2025-06-09 | 4 | View |
| 2025-06-05 | S-8 | View |
| 2025-06-05 | 8-K | View |
| 2025-05-15 | SCHEDULE 13G/A | View |
| 2025-05-12 | SCHEDULE 13G/A | View |
| 2025-05-08 | 10-Q | View |